Aytu BioPharma Inc
Company Profile
Business description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Contact
7900 East Union Avenue
Suite 920
DenverCO80237
USAT: +1 720 437-6580
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
83
Stocks News & Analysis
stocks
Coca-Cola earnings: Innovation and brand strength underpin growth
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,321.10 | 10.80 | -0.12% |
CAC 40 | 8,229.49 | 29.37 | -0.36% |
DAX 40 | 24,322.75 | 7.28 | -0.03% |
Dow JONES (US) | 46,924.74 | 218.16 | 0.47% |
FTSE 100 | 9,489.53 | 62.54 | 0.66% |
HKSE | 25,807.71 | 219.84 | -0.84% |
NASDAQ | 22,953.67 | 36.88 | -0.16% |
Nikkei 225 | 49,307.79 | 8.27 | -0.02% |
NZX 50 Index | 13,306.44 | 71.41 | -0.53% |
S&P 500 | 6,735.35 | 0.22 | 0.00% |
S&P/ASX 200 | 9,030.00 | 10.30 | -0.11% |
SSE Composite Index | 3,913.76 | 2.57 | -0.07% |